Clinical trial
A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.
NCT00935987 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- April 30, 2012
- Enrollment
- 166 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis